| EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma | 2018/07/01 | English | 5,050 |
| EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma | 2012/04/01 | English | 4,136 |
| Histological grading and staging of chronic hepatitis | 1995/06/01 | English | 3,551 |
| EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection | 2017/08/01 | English | 3,272 |
| EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease | 2016/06/01 | English | 2,858 |
| EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection | 2012/07/01 | English | 2,299 |
| Expanding consensus in portal hypertension | 2015/09/01 | English | 2,151 |
| A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement | 2020/07/01 | English | 2,030 |
| Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies | 2006/01/01 | English | 1,967 |
| Burden of liver diseases in the world | 2019/01/01 | English | 1,908 |
| NAFLD: A multisystem disease | 2015/04/01 | English | 1,813 |
| The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide | 2006/10/01 | English | 1,722 |
| EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis | 2018/08/01 | English | 1,540 |
| BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update | 2022/03/01 | English | 1,465 |
| Global epidemiology and genotype distribution of the hepatitis C virus infection | 2014/11/01 | English | 1,337 |
| EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis | 2015/07/01 | English | 1,256 |
| Non-alcoholic fatty liver disease – A global public health perspective | 2019/03/01 | English | 1,231 |
| EASL Recommendations on Treatment of Hepatitis C 2018 | 2018/08/01 | English | 1,187 |
| EASL Clinical Practice Guidelines: Management of cholestatic liver diseases | 2009/08/01 | English | 1,184 |
| The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis | 2019/10/01 | English | 1,183 |
| EASL Clinical Practice Guidelines: Management of chronic hepatitis B | 2009/02/01 | English | 1,112 |
| EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis | 2010/09/01 | English | 1,100 |
| Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030 | 2018/10/01 | English | 1,064 |
| Non-invasive evaluation of liver fibrosis using transient elastography | 2008/05/01 | English | 1,001 |
| Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension | 2010/10/01 | English | 1,001 |
| Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma | 2014/06/01 | English | 946 |
| Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease | 2015/03/01 | English | 940 |
| Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors | 2008/02/01 | English | 907 |
| The gut-liver axis in liver disease: Pathophysiological basis for therapy | 2020/03/01 | English | 901 |
| Baveno VII – Renewing consensus in portal hypertension | 2022/04/01 | English | 888 |